Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:21:35.152Z.
Calculation as of: 2026-10-06T17:21:35.152Z.
Quote observation: 2026-10-06T17:20:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.92B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.90B
Price/FCF Ratio
N/A
TTM Avg
44.84
3Y Avg
44.84
5Y Avg
44.84
Market Cap
$1.95B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.89B
Price/FCF Ratio
N/A
TTM Avg
547.75
3Y Avg
444.15
5Y Avg
642.22
Market Cap
$1.97B
Price/FCF Ratio
778.86
TTM Avg
497.87
3Y Avg
11182.67
5Y Avg
11182.67
Market Cap
$1.98B
Price/FCF Ratio
16.87
TTM Avg
21.03
3Y Avg
765.32
5Y Avg
894.72
Market Cap
$1.85B
Price/FCF Ratio
11.65
TTM Avg
12.50
3Y Avg
25.31
5Y Avg
28.24
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.92B | N/A | N/A | N/A | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | N/A | 44.84 | 44.84 | 44.84 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.95B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.89B | N/A | 53.35 | 53.35 | 53.35 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | N/A | 547.75 | 444.15 | 642.22 |
| AxoGen, Inc. (AXGN)vs › | $1.97B | 778.86 | 497.87 | 11182.67 | 11182.67 |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 16.87 | 21.03 | 765.32 | 894.72 |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 11.65 | 12.50 | 25.31 | 28.24 |
| Azenta, Inc. (AZTA)vs › | $1.84B | 186.31 | 56.48 | 95.26 | 92.20 |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.83B | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
